1352719-15-3

Basic information

• Product Name: (S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1352719-15-3
• Molecular Weight: 237.302
• Mol File: 1352719-15-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester(1352719-15-3)
• EPA Substance Registry System: (S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester(1352719-15-3)

Safety Data

• Hazardous Substances Data: 1352719-15-3(Hazardous Substances Data)

Usage

General Description

(S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C13H21N3O2. It is a derivative of the amino acid proline and belongs to the group of pyrrolidine carboxylic acid esters. (S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester is commonly used in organic synthesis and pharmaceutical research due to its potential biological activity and structural properties. It has been studied as a potential building block for the synthesis of various bioactive molecules and pharmaceutical drugs. The tert-butyl ester group provides stability to the compound and allows for easier manipulation in chemical reactions. Overall, (S) 2-(1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester is an important intermediate in organic chemistry and drug discovery applications.

Upstream product

• 170491-63-1 N-Boc-prolinol 
• 131543-46-9 Glyoxal 
• 69610-41-9 Boc-L-Pro-H 
• 59378-82-4 N-(tert-butoxycarbonyl)pyrrolidine-2-carboxaldehyde 

Downstream Products

• 1352718-88-7 2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid acid tert-butyl ester 
• 1312545-68-8 [(S)-1-((S)-2-{4-[4-(6-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-3H-imidazol-4-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carbonyl)-2-methylpropyl]carbamicacid methyl ester 
• 1312547-01-5 (S)-2-{5-[6-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)thieno[3,2-b]thiophen-3-yl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1352718-88-7 tert-butyl 2-(5-bromo-1H-imidazol-2-yl) pyrrolidine-1-carboxylate 

Relevant articles and documents

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.